德納利治療公司
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionStemPoint Capital LP
Latest Disclosed Ownership426,561 shares
Latest Disclosed Value $ 8,189,971
StemPoint Capital LP reports 1.79% increase in ownership of DNLI / Denali Therapeutics Inc.

On May 18, 2026 - StemPoint Capital LP filed a 13F-HR/A form disclosing ownership of 426,561 shares of Denali Therapeutics Inc. (US:DNLI) valued at $8,189,971 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 419,058 shares of Denali Therapeutics Inc.. This represents a change in shares of 1.79% during the quarter. The current value of the position is $8,590,939 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-18 2026-03-31 13F/A-1 DENALI THERAPEUTICS COM 24823R105 426,561 7,503 1.79 8,190 18.37 1.5500
2026-05-15 2026-03-31 13F DENALI THERAPEUTICS COM 24823R105 426,561 7,503 8,190 1.5905
2026-02-17 2025-12-31 13F DENALI THERAPEUTICS COM 24823R105 419,058 -1,315,601 -75.84 6,919 -72.53 1.1863
2025-11-14 2025-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,734,659 1,026,744 145.04 25,187 154.34 5.0466
2025-08-14 2025-06-30 13F DENALI THERAPEUTICS COM 24823R105 707,915 40,837 6.12 9,904 9.21 3.1786
2025-05-15 2025-03-31 13F DENALI THERAPEUTICS COM 24823R105 667,078 82,750 14.16 9,069 -23.85 2.8909
2025-02-14 2024-12-31 13F DENALI THERAPEUTICS COM 24823R105 584,328 302,278 107.17 11,909 44.94 2.9728
2024-11-13 2024-09-30 13F DENALI THERAPEUTICS COM 24823R105 282,050 31,040 12.37 8,216 40.97 2.4598
2024-08-13 2024-06-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 251,010 251,010 5,828 1.7128
2024-08-13 2024-06-30 13F DENALI THERAPEUTICS COM 24823R105 251,010 251,010 5,828 1.7050
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.